Nuclear Medicine Communications最新文献

{"title":"Efficacy of intra-arterial [ 177 Lu]Lu-DOTATATE vs. continuation intravenous [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy in nonresponding locally advanced inoperable or liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors.","authors":"Rangat Bagasariya, Rahul Vithalrao Parghane, Nitin Shetty, Kunal Gala, Suyash Kulkarni, Sandip Basu","doi":"10.1097/MNM.0000000000002173","DOIUrl":"10.1097/MNM.0000000000002173","url":null,"abstract":"<p><strong>Background: </strong>Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrating liver-dominant inoperable metastatic diseases or locally advanced inoperable tumors may at times show reduced efficacy for intravenous peptide receptor radionuclide therapy (PRRT).</p><p><strong>Aims and objectives: </strong>To determine and compare the outcome of intra-arterial [ 177 Lu]Lu-DOTATATE PRRT in GEP-NET with locally advanced inoperable primary or liver-dominant metastases who had shown no response after at least two cycles of intravenous [ 177 Lu]Lu-DOTATATE, as compared to those patients who continued intravenous [ 177 Lu]Lu-DOTATATE only.</p><p><strong>Materials and methods: </strong>GEP-NET patients with locally advanced inoperable primary or liver metastatic disease, who exhibited nonresponsive disease (either stable or progressive disease on anatomical imaging evaluation) after at least two cycles of intravenous [ 177 Lu]Lu-DOTATATE PRRT, were administered intra-arterial [ 177 Lu]Lu-DOTATATE PRRT (group A). For comparison, matched controls [age, gender, primary site, tumor grade, proliferation index, disease burden, and [ 18 F]fluorodeoxyglucose (FDG) PET/computed tomography status] who had received only intravenous [ 177 Lu]Lu-DOTATATE PRRT (group B) were selected retrospectively. The data were compared and analyzed for response assessments across three categories (symptomatic, including various quality-of-life scores; biochemical; and imaging), survival outcomes, and toxicity profiles.</p><p><strong>Results: </strong>A total of 33 GEP-NET patients (group A-11 and group B-22) were included. Symptomatic alleviation was slightly higher in group A compared with group B (75 vs. 66.8%), with higher quality-of-life (QoL) scores in group A. According to RECIST 1.1, group A had a 36.3% objective response rate compared with 13.6% in group B. Group A had a higher disease control rate (90.8%) than group B (77.2%). The median progression-free survival (PFS) was significantly longer in group A (not attained) compared with group B (median PFS of 22 months; P < 0.05). No major toxicity was observed in either group.</p><p><strong>Conclusion: </strong>Intra-arterial [ 177 Lu]Lu-DOTATATE resulted in a higher response rate, symptomatic relief, improved QoL, and prolonged PFS in patients whose disease remained nonresponsive after intravenous [ 177 Lu]Lu-DOTATATE. Prospective randomized controlled trials can further validate the incorporation of intra-arterial PRRT into the management of GEP-NETs.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1029-1040"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147988591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolutionary landscape and collaborative networks of global theranostic research in nuclear medicine: a visual bibliometric analysis.","authors":"Ying-Nan Jia, Qian Wu, Pei-Hui Liu","doi":"10.1097/MNM.0000000000002183","DOIUrl":"10.1097/MNM.0000000000002183","url":null,"abstract":"<p><strong>Background: </strong>Theranostics, integrating diagnostic imaging with targeted radionuclide therapy, has become central to nuclear medicine, but its global research landscape and collaboration patterns remain incompletely mapped.</p><p><strong>Objective: </strong>To characterize publication dynamics, cooperative networks, and emerging topics in theranostic research from 2006 to 2024.</p><p><strong>Methods: </strong>Articles and reviews indexed in the Web of Science Core Collection were retrieved for bibliometric analysis. Excel, CiteSpace, VOSviewer, Scimago Graphica, ArcGIS, and the R package bibliometrix were used for quantitative analysis and visualization.</p><p><strong>Results: </strong>A total of 1801 articles and reviews were included, with a compound annual growth rate of 18.7%. The USA, Germany, and China were the leading producer countries, and the USA-Germany collaboration showed the strongest bilateral link strength. The Helmholtz Association, Memorial Sloan Kettering Cancer Center, and the University of California System were the most productive institutions, while Herrmann K., Wester H.J., and Werner R.A. led individual output. Keyword co-occurrence analysis identified five major themes: prostate-specific membrane antigen (PSMA)-targeted imaging and therapy, somatostatin receptor-based peptide therapy, neuroendocrine tumors, alpha-particle therapy, and fibroblast activation protein-targeted probes. Burst detection showed that fibroblast activation protein, actinium-225, and 177 Lu-PSMA-617 have emerged as recent research hotspots.</p><p><strong>Conclusion: </strong>Theranostic research in nuclear medicine has expanded rapidly over the past two decades, with a trans-Atlantic and Asia-Pacific collaborative pattern. Current frontiers are shifting from beta-emitters toward alpha-emitters and tumor-microenvironment-targeted probes. Greater intercontinental cooperation and continued focus on novel radionuclides and under-explored targets may support future innovation and clinical translation.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1049-1061"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13440549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147988642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[ 18 F]fluorodeoxyglucose PET/MRI for nononcological musculoskeletal indications: reference uptake values in the asymptomatic lumbar spine and example comparison to a low back pain patient.","authors":"Jacob M Mostert, Edwin H G Oei, Denise W J van Beekveld, Sandip Biswal, Rianne A van der Heijden","doi":"10.1097/MNM.0000000000002164","DOIUrl":"10.1097/MNM.0000000000002164","url":null,"abstract":"<p><strong>Objective: </strong>To assess normal [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) uptake values in lumbar spine structures on PET/MRI in patients without low back pain.</p><p><strong>Methods: </strong>Asymptomatic adults receiving whole-body FDG PET/MRI for nononcological indications were prospectively included. Spinal structures of interest were manually annotated at each lumbar level. Maximum standardized uptake value (SUV max ) and mean SUV (SUV mean ) values were extracted from ordered subset expectation maximization, block sequential regularized expectation maximization (BSREM) β450, and BSREM β300 images. The distributions of SUV max and SUV mean values were evaluated across spinal levels and structures. We also evaluated normalization of SUV metrics with the liver and subcutaneous fat uptake values, and correlations between SUV metrics and BMI, age, and blood glucose level.</p><p><strong>Results: </strong>Twenty-two patients were included for analysis. Average SUV max on OSEM reconstructions was 2.99 (SD: 0.69) for the vertebral body and 1.95 (SD: 0.54) for the intervertebral disc. In the nervous system, SUV max for articular, peri-articular, and ligamentous structures was lower, ranging between 1.26 and 1.62. Uptake values were significantly lower on BSREM β450 and higher on BSREM β300. There was a positive correlation between uptake values and BMI, but no correlation was found with age or blood glucose level.</p><p><strong>Conclusion: </strong>Normal uptake values in the lumbar spine on [ 18 F]FDG PET/MRI in asymptomatic adults were assessed. The uptake values reported in this study could serve as a reference for the identification of abnormalities in patients with chronic low back pain, but the applied PET reconstruction method and patient BMI should be taken into account.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1072-1080"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13440533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From 18 F-choline to prostate-specific membrane antigen PET: lessons from early multiparametric kinetic modelling in prostate cancer.","authors":"Athar Haroon, Ahmad Almuhaideb, Sola Adeleke, Raymond Endozo, Kjell Erlandsson, Ghulam Mustafa Shah Syed, Mark Emberton, Jamshed Bomanji","doi":"10.1097/MNM.0000000000002166","DOIUrl":"10.1097/MNM.0000000000002166","url":null,"abstract":"<p><strong>Background: </strong>We revisited our early multiparametric dynamic choline PET data to demonstrate methodological feasibility for kinetic modelling and to highlight lessons relevant for current prostate-specific membrane antigen (PSMA) PET protocols.</p><p><strong>Methods: </strong>Nine men (aged 48-81 years) with biochemical recurrence of prostate cancer (prostate-specific antigen [PSA] range: 0.12-45.1 μg/L) underwent dynamic 18 F-FECH PET/computed tomography. Patlak analysis produced two outcome values, influx rate ( Ki ) and volume of distribution. For quantitative analysis region of interests (ROIs) were drawn on a metabolically active focus of the prostate. For semiquantitative analysis the tracer accumulation in the ROIs was measured using the standardised uptake value. Arterial input functions were derived visually, and Patlak graphical analysis was performed. Correlations were explored between kinetic parameters, Gleason grade, and serum PSA. Spearman's correlation coefficients were calculated to assess the possible association between 18 F choline uptake, clinical and histopathological characteristics.</p><p><strong>Results: </strong>Dynamic acquisitions were technically feasible and analyzable before urinary excretion obscured the prostate. Time-activity curves plateaued after 1-2 min, and Patlak plots showed bilinear behaviour with measurable Ki and volume of distribution. Cancerous prostate tissue demonstrated increased perfusion compared with background tissue. No significant correlation was observed between kinetic parameters and PSA or Gleason grade.</p><p><strong>Conclusion: </strong>Dynamic 18 F-choline PET provided quantitative kinetic parameters reflective of tumour perfusion. Although choline imaging has been largely superseded by PSMA PET because of superior tumour-to-background contrast and specificity, the technical principles established in this study remain directly applicable to current PSMA kinetic and parametric imaging.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1088-1101"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement uncertainty in three sample glomerular filtration rate tests.","authors":"Dexter Scott, Emma Norman, Alexander J Smout, Phoebe Lipscomb-Stevens, Andrew J Fenwick, Andrew P Robinson, James W Scuffham","doi":"10.1097/MNM.0000000000002161","DOIUrl":"10.1097/MNM.0000000000002161","url":null,"abstract":"<p><strong>Objectives: </strong>To provide an estimate of the uncertainties associated with the measurement of the glomerular filtration rate using the three-sample method.</p><p><strong>Methods: </strong>Retrospective data from 2063 patients whose glomerular filtration rate (GFR) was evaluated with Tc-99m diethylenetriaminepentaacetic acid using a three-sample method were compiled for this analysis. Input quantities to the GFR measurement were modelled as probability density functions (PDFs), and a Monte-Carlo method of propagating these PDFs was used to assess overall uncertainty in the measured GFR for each patient.</p><p><strong>Results: </strong>The average uncertainty in the three-sample slope-intercept GFR was found to be 1.53% (with a coverage factor of k  = 1). The dominant source of uncertainty in the slope-intercept GFR was the injected activity measurement using the radionuclide calibrator, except for slope-intercept GFRs below 20 ml/min whose dominant source of uncertainty was counting statistics. The Brøchner-Mortensen correction for the unmeasured initial plasma clearance phase became the dominant source of uncertainty in absolute GFR values above 20 ml/min, increasing the average uncertainty to 3.32% ( k  = 1). The uncertainty in the absolute GFR was found to increase with increasing absolute GFR, because the Brøchner-Mortensen correction was associated with higher uncertainties for high GFRs.</p><p><strong>Conclusion: </strong>We have developed a framework to assess the measurement uncertainty in three-sample GFR studies for individual patients. While the uncertainty in the slope-intercept GFR is low, empirical corrections applied to derive the absolute GFR increase the uncertainty. Inclusion of measurement uncertainties in clinical GFR reports may aid clinical decision making, particularly in borderline cases.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1062-1071"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional detection of Bethesda greater than or equal to III cytology in cold thyroid nodules beyond American College of Radiology Thyroid Imaging Reporting and Data System risk stratification.","authors":"Ilona Lavender, Dee Nandurkar","doi":"10.1097/MNM.0000000000002174","DOIUrl":"10.1097/MNM.0000000000002174","url":null,"abstract":"<p><strong>Background: </strong>Cold thyroid nodules identified on nuclear medicine scintigraphy have historically been associated with increased malignancy risk. However, contemporary practice relies primarily on ultrasound risk stratification systems such as the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) to guide fine needle aspiration (FNA). The additional value of scintigraphy beyond ultrasound risk stratification remains uncertain.</p><p><strong>Aim: </strong>To determine whether scintigraphy identifies nodules with Bethesda greater than or equal to III cytology beyond ACR TI-RADS FNA criteria.</p><p><strong>Methods: </strong>A retrospective review of thyroid nodules undergoing ultrasound, nuclear medicine scintigraphy, and FNA was performed. Nodules with reduced uptake were classified as cold nodules. Cytology was classified using the Bethesda System, with Bethesda greater than or equal to III considered clinically significant.</p><p><strong>Results: </strong>A total of 235 cold thyroid nodules were identified. Of these, 169 met ACR TI-RADS FNA criteria, with 34 (20.1%) demonstrating Bethesda greater than or equal to III cytology. Sixty-six nodules below TI-RADS FNA thresholds underwent FNA because of cold scintigraphic findings, of which seven (10.6%) demonstrated Bethesda greater than or equal to III cytology. Overall, seven of 41 nodules (17.1%) with Bethesda greater than or equal to III cytology were identified solely because of scintigraphic appearance.</p><p><strong>Conclusion: </strong>Most Bethesda greater than or equal to III cytology occurred in nodules already meeting ACR TI-RADS FNA criteria. Cold scintigraphy identified few additional nodules below ultrasound FNA thresholds, suggesting limited additional detection beyond ultrasound risk stratification.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1041-1048"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment response evaluation in extraspinal musculoskeletal tuberculosis using molecular imaging (18F-fluorodeoxyglucose PET/computed tomography): a prospective observational study.","authors":"Roshan Banjara, Dilip Kumar Sankhwar, Ashish Dutt Upadhyay, Jaiben George, Rakesh Kumar, Vivek Shankar, Venkatesan Sampath Kumar, Shah Alam Khan","doi":"10.1097/MNM.0000000000002231","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002231","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to evaluate the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in monitoring treatment response and determining treatment end points in patients with extraspinal musculoskeletal tuberculosis (MSK-TB) receiving anti-tubercular therapy (ATT).</p><p><strong>Methods: </strong>In this prospective observational study, 62 patients with extraspinal MSK-TB underwent baseline 18F-FDG PET/CT before ATT, with follow-up scans at 6, 12, and 18 months. Total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax), and lesion-to-liver standardized uptake value ratio (SUVR) were recorded. Clinical, laboratory, and MRI findings were used as reference standards for healing. Receiver operating characteristic analysis identified PET/CT parameters associated with ATT beyond 18 months.</p><p><strong>Results: </strong>Fifty-one patients completed the final PET/CT follow-up. Significant reductions in TLG, SUVmax, and SUVR were observed during treatment (all P < 0.05). ROC analysis demonstrated that a ≤43% reduction in TLG, ≤46% reduction in SUVmax, and ≤26% reduction in SUVR between baseline and 6-month scans, and a ≤66% reduction in TLG, ≤36% reduction in SUVmax, and ≤30% reduction in SUVR between baseline and 12-month scans, were associated with the requirement for ATT beyond 18 months. The mean time to complete clinicoradiological healing was 19.23 ± 1.49 months, whereas the mean time to complete metabolic response on PET/CT was 18.54 ± 2.27 months, with no statistically significant difference (P = 0.30).</p><p><strong>Conclusion: </strong>18F-FDG PET/CT is a valuable tool for monitoring treatment response in extraspinal MSK-TB. Early changes in PET/CT parameters may predict treatment duration, and PET/CT findings closely correlate with disease healing, supporting its use in guiding individualized ATT duration.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-photon emission computed tomography/computed tomography-based radiomics of bone metastases for predicting epidermal growth factor receptor mutation status and targeted therapy efficacy in non-small-cell lung cancer.","authors":"Xiangxiang Li, Shasha Hou, Shen Wang, Qiang Jia, Wei Zheng","doi":"10.1097/MNM.0000000000002232","DOIUrl":"10.1097/MNM.0000000000002232","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop a single-photon emission computed tomography/computed tomography (SPECT/CT)-based radiomics model using bone metastases to predict epidermal growth factor receptor (EGFR) mutation status and the efficacy of targeted therapy in patients with non-small-cell lung cancer.</p><p><strong>Methods: </strong>This retrospective study included 240 patients with non-small-cell lung cancer. Among them, 205 were analyzed for the EGFR-mutation prediction model, and 210 for the targeted therapy efficacy model. Baseline and post-treatment whole-body SPECT/CT bone scans with maximum standardized uptake value (SUVmax) were acquired. Radiomic features from bone-metastasis SPECT/CT images were selected by minimum redundancy maximum relevance and least absolute shrinkage and selection operator regression. Seven machine learning algorithms were assembled to construct predictive models, whose performance was assessed via receiver operating characteristic curves, calibration curves, decision-curve analysis, and SHapley Additive exPlanations for model interpretability.</p><p><strong>Results: </strong>Among the seven machine learning models, the eXtreme Gradient Boosting model was the optimal. For the clinical-radiomics-SUVmax EGFR-mutation model, predictive factors included BMI, nonsmoking status, aspartate aminotransferase, leukocyte counts, erythrocyte counts, and SUVmax; the area under the receiver operating characteristic curve (AUC) values were 0.867 [95% confidence interval (CI): 0.823-0.911, training] and 0.834 (95% CI: 0.757-0.911, validation). For the radiomics-ΔSUVmax efficacy model (ΔSUVmax > -0.18), AUCs reached 0.869 (95% CI: 0.828-0.910, training) and 0.846 (95% CI: 0.769-0.923, validation) (all P < 0.05).</p><p><strong>Conclusion: </strong>SPECT/CT-derived bone metastasis radiomics offers complementary information for predicting EGFR mutation and targeted therapy efficacy. Models integrating clinical and metastatic‑lesion features may facilitate individualized treatment decision‑making.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole body fluorine-18 fluorodeoxyglucose parametric PET/computed tomography in people with long coronavirus disease: the ERASE-LC trial protocol.","authors":"Hairil Rashmizal Abdul Razak, W David Strain, Patrick Rogers, Mark A Faghy, Lindsay Skipper, Sascha H Kranen, Kinan Mokbel, Tom Bewick, Ruth Ashton, Kayle-Anne Sands, Helen Neilens, Amber Lord, Helen Hambly, Jade Chynoweth, Victoria Allgar, Michelle Scott-Cleasby, Jackie Hoare, Karen M Knapp","doi":"10.1097/MNM.0000000000002229","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002229","url":null,"abstract":"<p><p>The ERASE-LC feasibility trial will evaluate the feasibility of using remdesivir for the treatment of long coronavirus disease (COVID) with a wide range of outcome measures. This paper focuses on the nested parametric PET/computed tomography study and outlines the novel protocol utilized. The PET/computed tomography scans will be performed at one of the sites in 20 participants with an overall recruitment target of 72 participants across both centers. The PET/computed tomography scans will be performed at day 11 for the baseline scan and day 55 for the follow-up scan, with an estimated effective radiation dose of approximately 22 mSv under typical study conditions and a maximum anticipated exposure of 31.2 mSv. Dynamic scans will be acquired using the FlowMotion acquisition on a Siemens Biograph Vision 600 scanner with an acquisition time of 75-90 min depending on the height of the participant. Patient and public involvement and engagement was undertaken throughout the study design. The early experiences of performing this protocol demonstrated that participants were able to tolerate the scan duration and positioning. In conclusion, this protocol demonstrates a novel use of parametric PET/computed tomography fluorine-18 fluorodeoxyglucose whole body scans for the assessment of long COVID and response to remdesivir.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics of planar Tc-99m methylene diphosphonate bone scintigraphy for pediatric osteomyelitis: a paired infected-contralateral analysis.","authors":"Jagrati Chaudhary, Rakesh Kumar, Bhoomi Gupta, Param D Sharma, Ravi Mittal, Anil Kumar Pandey","doi":"10.1097/MNM.0000000000002234","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002234","url":null,"abstract":"<p><strong>Background: </strong>Pediatric osteomyelitis is a serious bone infection whose early diagnosis remains challenging because clinical and laboratory findings are often nonspecific. Although Tc-99m methylene diphosphonate (MDP) bone scintigraphy is highly sensitive for detecting osteoblastic activity and multifocal disease, image interpretation remains largely qualitative and subject to interobserver variability. This study evaluated whether radiomics analysis of planar Tc-99m MDP bone scintigraphy could quantitatively differentiate infected from contralateral normal bone in children with suspected osteomyelitis.</p><p><strong>Methods: </strong>This retrospective single-center study included 28 pediatric patients with suspected osteomyelitis who underwent anterior and posterior planar Tc-99m MDP bone scintigraphy. Paired infected and contralateral normal bone regions of interest (ROIs) of each patient were segmented. A standardized radiomics pipeline extracted 62 quantitative features per ROI, including shape, first-order intensity, and higher-order texture features. Statistical analyses included paired Wilcoxon signed-rank testing, effect size analysis, mutual information assessment, and leave-one-out cross-validated (LOOCV) logistic regression. A compact multivariable radiomics score was subsequently derived from the top-performing features.</p><p><strong>Results: </strong>Texture-based radiomic features showed the strongest discrimination between infected and contralateral bone, with gray-level co-occurrence matrix-derived correlation and information-theoretic metrics - particularly T_InformationCorrelation2Averaged2D, T_InformationCorrelation2SliceMerged2D, and T_CorrelationAveraged2D/T_CorrelationSliceMerged2D - demonstrating highly significant differences (all P < 0.001) and large paired effect sizes (Cohen's d ≈ 0.80-0.85). Single-feature logistic regression models achieved moderate discrimination (LOOCV AUC: 0.60-0.63).</p><p><strong>Conclusion: </strong>Planar Tc-99m MDP bone scintigraphy radiomics differentiated infected from normal contralateral bone in pediatric osteomyelitis, with texture-derived features outperforming intensity metrics (all P < 0.001; Cohen's d ≈ 0.80-0.85), supporting radiomics as an objective adjunct to visual interpretation.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}